Healthcare provider profile · identity verified

Theodore Strange, MD

Internal Medicine · STATEN ISLAND, NY · NPI 1710972021

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	557	158
Atorvastatin Calcium	Atorvastatin Calcium	422	133
Benazepril Hcl	Benazepril Hcl	307	80
Simvastatin	Simvastatin	303	92
Losartan Potassium	Losartan Potassium	256	64
Lisinopril	Lisinopril	221	61
Hydrochlorothiazide	Hydrochlorothiazide	203	51
Metformin Hcl	Metformin Hcl	195	58
Levothyroxine Sodium	Levothyroxine Sodium	171	48
Rosuvastatin Calcium	Rosuvastatin Calcium	125	35
Zolpidem Tartrate	Zolpidem Tartrate	123	20
Metoprolol Succinate	Metoprolol Succinate	105	32
Citalopram Hbr	Citalopram Hydrobromide	102	29
Ozempic	Semaglutide	83	12
Eliquis	Apixaban	75	15
Tamsulosin Hcl	Tamsulosin Hcl	74	21
Metoprolol Tartrate	Metoprolol Tartrate	73	21
Donepezil Hcl	Donepezil Hcl	72	15
Atenolol	Atenolol	68	17
Pantoprazole Sodium	Pantoprazole Sodium	64	23
Meloxicam	Meloxicam	62	20
Furosemide	Furosemide	59	21
Farxiga	Dapagliflozin Propanediol	57	13
Sertraline Hcl	Sertraline Hcl	56	14
Omeprazole	Omeprazole	55	18
Alprazolam	Alprazolam	51	18
Synthroid	Levothyroxine Sodium	49	12
Escitalopram Oxalate	Escitalopram Oxalate	46	13
Albuterol Sulfate Hfa	Albuterol Sulfate	45	suppressed
Jardiance	Empagliflozin	45	15
Carvedilol	Carvedilol	41	11
Potassium Chloride	Potassium Chloride	41	suppressed
Xarelto	Rivaroxaban	38	suppressed
Glimepiride	Glimepiride	37	suppressed
Pravastatin Sodium	Pravastatin Sodium	37	11
Valsartan	Valsartan	35	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	32	suppressed
Allopurinol	Allopurinol	30	suppressed
Trazodone Hcl	Trazodone Hcl	28	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Famotidine	Famotidine	27	suppressed
Finasteride	Finasteride	27	suppressed
Mounjaro	Tirzepatide	26	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Fenofibrate	Fenofibrate	23	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Glipizide Er	Glipizide	21	suppressed
Prednisone	Prednisone	21	11
Silodosin	Silodosin	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Risedronate Sodium	Risedronate Sodium	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	suppressed
Gabapentin	Gabapentin	16	suppressed
Montelukast Sodium	Montelukast Sodium	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Amoxicillin	Amoxicillin	14	12
Carbidopa-Levodopa	Carbidopa/Levodopa	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Indapamide	Indapamide	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Ranolazine Er	Ranolazine	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	11	suppressed
Fluticasone Propionate	Fluticasone Propionate	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error